In continuous subcutaneous insulin infusion (CSII) therapy, bolus doses are delivered to cover meals and to correct high blood glucose values. Data for bolus dosing accuracy were already presented for different insulin pump systems. In this study, two lately released insulin pumps were tested accordingly.

Two new insulin pumps (MiniMed® 670G and mylife™ YpsoPump®) with soft cannula were tested. In an experimental setting following EN 60601-2-24, both pumps were installed with the tip of the cannula in a water-filled beaker placed on an electronic balance. To avoid evaporation an oil film was applied. After a run-in period, 25 successive 1.0 U and 0.1 U boluses and 12 successive 10 U boluses were delivered and weighed individually. In addition, time for a bolus delivery of 10 U was recorded. Each insulin pump was tested 9 times.

While for 10 U and 1 U boluses 100% of deliveries of both pumps were within ±15% of target, only 85% (670G) and 88% (YpsoPump), respectively, of 0.1 U boluses were within these limits. Delivery time of a 10 U bolus was different between the two pumps, 6.7 min (standard speed) and 43 sec (quick) for 670G vs. 19 sec for YpsoPump, but complied with the respective manufacturer’s labeling.

These results fit to the previously tested durable insulin pumps for which similar percentages of deliveries within ±15% of target (100% for 10 and 1 U and 71% to 96% for 0.1 U) were observed. As delivery accuracy decreases with smaller bolus doses, care should be given especially when treating small children with CSII.

Disclosure

R. Ziegler: Advisory Panel; Self; Abbott, Lilly Diabetes, Novo Nordisk A/S, Roche Diabetes Care. D. Waldenmaier: None. J. Mende: None. C. Haug: None. G. Freckmann: Advisory Panel; Self; Abbott, Novo Nordisk Pharma GmbH, Sensile Medical AG. Consultant; Self; Metronom Health Europe, Roche Diabetes Care, Sanofi. Speaker’s Bureau; Self; Ascensia Diabetes Care, Dexcom, Inc., Ypsomed AG.

Funding

Roche Diabetes Care GmbH

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.